Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)
Completed
GlaxoSmithKline
Phase 3
2005-09-01
The incidence of type 2 diabetes is on the increase. According to recent Canadian Diabetes
Association guidelines glucose control, based on the A1C measurement, needs to be achieved
within a 6-12 month period of time after the initial diagnosis of type 2 diabetes. The
guidelines on the use of antihyperglycemic agents identify the potential benefits of
sub-maximal oral combination therapy in order to achieve more rapid and improved glycemic
control compared with higher dose monotherapy. Furthermore, many patients on prolonged oral
antihyperglycemic monotherapy who then start on combination therapy may not achieve the
required target glycemic control. Indeed early initiation of combination therapies may be
necessary to achieve and maintain glycemic targets because of the progressive deterioration
of pancreatic β cell function and glycemic control.
Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)
Completed
Canadian Heart Research Centre
Phase 3
2005-09-01
The incidence of type 2 diabetes is on the increase. According to recent Canadian Diabetes
Association guidelines glucose control, based on the A1C measurement, needs to be achieved
within a 6-12 month period of time after the initial diagnosis of type 2 diabetes. The
guidelines on the use of antihyperglycemic agents identify the potential benefits of
sub-maximal oral combination therapy in order to achieve more rapid and improved glycemic
control compared with higher dose monotherapy. Furthermore, many patients on prolonged oral
antihyperglycemic monotherapy who then start on combination therapy may not achieve the
required target glycemic control. Indeed early initiation of combination therapies may be
necessary to achieve and maintain glycemic targets because of the progressive deterioration
of pancreatic β cell function and glycemic control.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
